Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference
June 05 2023 - 7:00AM
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage
biopharmaceutical company developing a novel class of injectable
biologics to selectively engage and modulate disease-specific T
cells directly within the patient’s body, announced today that it
will present at the Jefferies Global Healthcare Conference being
held June 7–9, 2023 in New York.
The Company will provide a corporate update highlighting the
most recent clinical progress for CUE-101, its lead clinical asset
from the interleukin 2 (IL-2)-based CUE-100 series, being evaluated
as monotherapy and in combination with pembrolizumab (KEYTRUDA®)
for the treatment of patients with recurrent/metastatic HPV16+ head
and neck cancer. The presentation will also provide an update on
the second clinical drug candidate from the IL-2-based CUE-100
series, CUE-102, for patients with Wilms’ Tumor 1 (WT1)-positive
cancers, as well as CUE-401, a bispecific protein designed to
induce and expand regulatory T cells (Tregs) for the treatment of
autoimmune and inflammatory diseases.
Presentation DetailsJefferies 2023
Global Healthcare Conference Date and
Time: Friday, June 9 at 12:15 p.m. EDT Webcast
Link: https://wsw.com/webcast/jeff281/cue/1688830
A live and archived webcast of the presentation will be
available in the Investor and Media section of the Company’s
website at www.cuebiopharma.com. The webcast will be archived
for 30 days.
About the CUE-100 Series The CUE-100
series consists of Fc-fusion biologics that incorporate peptide-MHC
(pMHC) molecules along with rationally engineered IL-2 molecules.
This singular biologic is anticipated to selectively target,
activate and expand a robust repertoire of tumor-specific T cells
directly in the patient’s body. The binding affinity of IL-2 for
its receptor has been deliberately attenuated to achieve
preferential selective activation of tumor-specific effector T
cells while reducing the potential for effects on regulatory T
cells (Tregs) or broad systemic activation, potentially mitigating
the dose-limiting toxicities associated with current IL-2-based
therapies.
About Cue BiopharmaCue Biopharma, a
clinical-stage biopharmaceutical company, is developing a novel
class of injectable biologics to selectively engage and modulate
disease-specific T cells directly within the patient’s body. The
company’s proprietary platform, Immuno-STAT™ (Selective
Targeting and Alteration of T cells) and biologics are
designed to harness the body’s intrinsic immune system as T cell
engagers without the need for ex vivo manipulation or broad
systemic modulation.
Headquartered in Boston, Massachusetts, we are led by
an experienced management team and independent Board of Directors
with deep expertise in immunology and immuno-oncology as well as
the design and clinical development of protein biologics.
For more information please
visit www.cuebiopharma.com and follow us on Twitter
at https://twitter.com/CueBiopharma.
Investor ContactMarie CampinellSenior Director,
Corporate CommunicationsCue Biopharma,
Inc.mcampinell@cuebio.com
Media ContactMaya RomanchukLifeSci
Communicationsmromanchuk@lifescicomms.com
Cue Biopharma (NASDAQ:CUE)
Historical Stock Chart
From May 2024 to Jun 2024
Cue Biopharma (NASDAQ:CUE)
Historical Stock Chart
From Jun 2023 to Jun 2024